Our pipeline

Pipeline—creating tomorrow's vaccines today

The world urgently needs new tools to help solve some of our greatest infectious disease challenges. At Novavax we are applying our unique technology to address current and emerging threats.

Novavax continually conducts clinical trials and investigations and gathers real-world evidence to develop vaccines aimed at addressing public health threats. Our scientists in our research and development (R&D) programs are committed to the efficient delivery of new vaccines while maintaining the safety of patients who take part in our trials.

Our pipeline

Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.

Our Matrix-M adjuvant technology

Matrix-M adjuvant

Investigational vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.

Learn more about our technology platform

Vaccines in Novavax Pipeline and Status
Therapeutic area
Candidate
Adjuvant Technology
Phase of trial
Authorized use
   
Preclinical
Phase 1
Phase 2
Phase 3
 
Novavax Clinical/Commercial Stage
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine
Matrix-M™ adjuvant
    
 
Authorized1
Novavax Clinical Stage
Respiratory diseases
COVID-19 + seasonal influenza
COVID-influenza combination (CIC) vaccine
Matrix-M™ adjuvant
  
 
Phase 2
 
Respiratory diseases
Seasonal influenza
Influenza vaccine (Older Adults)
Matrix-M™ adjuvant
  
 
Phase 2
 
Partnered Commercial Stage
Parasitic diseases
Malaria
R21/Matrix-M
Matrix-M™ adjuvant
    
 
Authorized2
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine
 
Authorized1
Matrix-M™ adjuvant
Novavax Clinical/Commercial Stage
Respiratory diseases
COVID-19 + seasonal influenza
COVID-influenza combination (CIC) vaccine
 
Phase 2
Matrix-M™ adjuvant
Novavax Clinical Stage
Respiratory diseases
Seasonal influenza
Influenza vaccine (Older Adults)
 
Phase 2
Matrix-M™ adjuvant
Parasitic diseases
Malaria
R21/Matrix-M
 
Authorized2
Matrix-M™ adjuvant
Partnered Commercial Stage

Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax™; and Nuvaxovid™, authorized in the U.S. under trade name, Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula); and authorized in the EU under the trade name Nuvaxovid XBB.1.5. Strain change trials for the COVID-19 vaccines ongoing. Authorization information can be found by country at https://novavaxcovidvaccine.com.


Authorized in Ghana, Nigeria, and Burkina Faso; Commercialized by Serum Institute of India and granted prequalification by the WHO.


*Developed and distributed by Oxford University and Serum Institute of India, using licensed Matrix-M technology.

Science & Technology

From the diseases that we're focused on to the details of our scientific approach

Science & Technology

Source in-depth information, including select clinical trial protocols

Who we are

Novavax is powered by global collaborations